Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,861	$ 963
Trade receivables	6,061	7,128
Inventories	4,971	4,924
Prepaid expenses	1,104	1,100
Other current assets	685	701
Assets held for sale	29	566
Total current assets	14,711	15,382
Deferred income taxes	440	574
Other non-current assets	806	932
Property, plant and equipment, net	7,213	7,673
Identifiable intangible assets, net	16,212	17,640
Goodwill	27,648	28,414
Total assets	67,030	70,615
Current liabilities:
Short-term debt	1,272	3,646
Sales reserves and allowances	7,138	7,881
Trade payables	1,779	2,069
Employee-related obligations	674	549
Accrued expenses	2,248	3,014
Other current liabilities	1,104	724
Liabilities held for sale		38
Total current liabilities	14,215	17,921
Long-term liabilities:
Deferred income taxes	2,668	3,277
Other taxes and long-term liabilities	1,814	1,843
Senior notes and loans	28,965	28,829
Total long-term liabilities	33,447	33,949
Commitments and contingencies, see note 16
Total liabilities	47,662	51,870
Teva shareholders' equity:
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; June 30, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	3,760	3,631
Ordinary shares of NIS 0.10 par value per share; June 30, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,124 million shares	54	54
Additional paid-in capital	23,426	23,479
Accumulated deficit	(2,864)	(3,808)
Accumulated other comprehensive loss	(2,289)	(1,848)
Treasury shares as of June 30, 2018 and December 31, 2017 - 106 million ordinary shares and 107 million ordinary shares, respectively	(4,149)	(4,149)
Stockholders' equity attributable to Teva shareholders	17,938	17,359
Non-controlling interests	1,430	1,386
Total equity	19,368	18,745
Total liabilities and equity	$ 67,030	$ 70,615